|1.||Bally, Marcel B: 4 articles (09/2015 - 01/2006)|
|2.||Kalra, Jessica: 4 articles (09/2015 - 01/2008)|
|3.||Dedhar, Shoukat: 4 articles (01/2009 - 01/2006)|
|4.||Mills, Gordon B: 3 articles (01/2007 - 08/2005)|
|5.||Waterhouse, Dawn: 2 articles (05/2011 - 01/2009)|
|6.||Yan, Hong: 2 articles (05/2011 - 01/2008)|
|7.||Warburton, Corinna: 2 articles (05/2011 - 01/2009)|
|8.||Daynard, Tim: 2 articles (01/2009 - 01/2008)|
|9.||Jasser, Samar A: 2 articles (01/2007 - 08/2005)|
|10.||Dunn, Sandra E: 2 articles (01/2007 - 01/2006)|
01/01/2007 - "Expression levels of ILK in SCCHN tumor specimens and cell lines and the efficacy of QLT0267 in inhibiting cell growth and inducing apoptosis in SCCHN cell lines. "
09/01/2012 - "Conversely, QLT0267 induced cell death in MM cell lines and most primary tumor samples via the intrinsic apoptotic pathway. "
01/01/2008 - "Mice treated with QLT0267 exhibited significant delays in tumor growth (treated 213 mm3 versus control 549 mm3). "
01/01/2007 - "We concluded that QLT0267 blocks the production of uPA providing a new target for the management of recurrent cancers."
01/01/2007 - "Immunohistochemical analysis of 17 SCCHN tumor tissue specimens and 3 normal tongue tissue specimens for ILK expression and in vitro analysis of the effectiveness of QLT0267 on SCCHN cells. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2009 - "The purpose of this study was to investigate the therapeutic potential of the ILK small molecule inhibitor, QLT0267 (267), alone or in combination with chemotherapies commonly used to treat breast cancer patients. "
09/01/2015 - "To facilitate this understanding, we used tumor tissue microarrays (TMA) and digital image analysis for quantification of immunohistochemistry (IHC) in order to investigate how QLT0267 affects signaling pathways in an orthotopic model of breast cancer over time. "
09/01/2015 - "A small molecule inhibitor (QLT0267) targeting integrin-linked kinase is able to slow breast tumor growth in vivo; however, the mechanism of action remains unknown. "
01/01/2006 - "The inhibition of PKB/Akt Ser473 phosphorylation by QLT-0267 in breast cancer cells was rescued by a kinase-active ILK mutant but not by a kinase-dead ILK mutant. "
01/01/2006 - "We show that inhibition of ILK activity with a pharmacologic ILK inhibitor, QLT-0267, results in the inhibition of PKB/Akt Ser473 phosphorylation, stimulation of apoptosis, and a decrease in mammalian target of rapamycin (mTOR) expression in human breast cancer cells. "
|3.||Sarcoma (Soft Tissue Sarcoma)
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/01/2009 - "On the basis of our previous findings clearly showing that ILK transduces antisurvival signals in cells exposed to ionizing radiation, this study evaluated the impact of the small molecule inhibitor QLT0267, reported as putative ILK inhibitor, on the cellular radiation survival response of human head and neck squamous cell carcinoma cells (hHNSCC). "
01/01/2009 - "The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck."
|2.||squamous cell of head and neck Carcinoma
|4.||Actins (F Actin)
|7.||Caspase 3 (Caspase-3)
|8.||Glycogen Synthase Kinase 3
|9.||Messenger RNA (mRNA)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)